jeremiah@devisedesigns.com, Author at Corcept Therapeutics

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 143 entries already.

Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.

Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.

October 25, 2018

Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.

October 25, 2018

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

October 18, 2018

Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.

September 19, 2018

Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.

September 19, 2018

Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.

September 19, 2018

Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.

September 19, 2018

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.

September 19, 2018

Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.

September 19, 2018

Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.

September 19, 2018